BLASUBCUTANEOUSINJECTABLE
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STEQEYMA is a monoclonal antibody biosimilar to ustekinumab, approved by the FDA on December 17, 2024, developed by Celltrion. It is administered subcutaneously and targets IL-12 and IL-23 pathways. The specific indications have not been disclosed in available data but align with the reference product's approved uses.
Growth
Early-stage biosimilar in growth phase with competitive intensity moderate (30% pressure); limited initial market size suggests small specialized team focused on rapid market penetration and referral builds.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar
Started Mar 2025
225 enrolled
Crohn DiseasePlaque Psoriasis
Career Relevance
STEQEYMA represents a career opportunity in biosimilar commercialization during a critical growth phase immediately post-approval. Professionals joining now will shape market positioning, payer negotiations, and referral networks in a competitive immunology space.
Brand Manager
Worked on STEQEYMA at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.